EVIDENCE of GENE EXPRESSION and ENZYME ACTIVITY By

Total Page:16

File Type:pdf, Size:1020Kb

EVIDENCE of GENE EXPRESSION and ENZYME ACTIVITY By STEROID HYDROXYLASES IN THE RAT BRAIN: EVIDENCE OF GENE EXPRESSION AND ENZYME ACTIVITY by SCOTT M. MacKENZIE B.Sc.(Hons) © Scott M. MacKenzie, March 2000 Thesis submitted for the degree of Doctor of Philosophy to the University of Glasgow Department of Medicine and Therapeutics UNIVERSITY OF GLASGOW Western Infirmary, Glasgow 1 ProQuest Number: 11007810 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 11007810 Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 G IA SG O W UNIVERSITY LIBRARY , liW ^ Abstract Aldosterone and corticosterone are the main mineralocorticoid and glucocorticoid products of the rat adrenal cortex. They share a common biosynthetic pathway until the final stage where the substrate deoxycorticosterone (DOC) is converted to either aldosterone or corticosterone by the actions of the enzymes aldosterone synthase (CYP11B2) or llp-hydroxylase (CYP11B1) respectively. These enzymes are the products of highly homologous genes whose expression, along with that of other components of the corticosteroidogenic pathway, was long thought to be confined to the adrenal cortex. In recent years, however, due to the advent of more sensitive molecular biological techniques, evidence has accumulated to suggest that this is not the case and that certain extra-adrenal tissues may be capable of autonomous aldosterone and corticosterone production. In chapter 3, RT-PCR was used to detect transcripts from the CYP11B1 and CYP11B2 genes in a number of different tissue types. The transcription of genes encoding other components of corticosteroidogenesis, such as the side-chain cleavage enzyme and adrenodoxin, was also examined. Of the tissues examined, only brain tissue was found to contain transcripts from all these genes. Chapter 4 describes attempts using an SDS-polyacrylamide gel electrophoresis and immunoblotting technique to show that these transcripts are translated within brain tissue to result in the enzymes themselves. This utilised two monoclonal antibodies raised against non-homologous regions of the rat aldosterone synthase and 11 P-hydroxylase enzymes. However, no evidence of translation in extra-adrenal tissue was obtained using this technique, despite the identification of a positive band corresponding to 11 p-hydroxylase in adrenal tissue fractions. 2 In chapter 5, the same antibodies were used to detect aldosterone synthase and 11 P-hydroxylase within extra-adrenal tissues by immunostaining methods. Using adrenal tissue sections, the two antibodies were found to be highly specific for their respective antigens and apparently free of the cross-reactivity which might be expected between such highly homologous enzymes. Positive staining was also produced in brain tissue, where the enzymes were found to colocalise within the hippocampus and the cerebellum. Although previously published work had established that steroidogenesis occurs in the glial cells of the central nervous system, strong positive staining within the Purkinje cells of the cerebellum in this study presented strong evidence for neuronal expression. Rigorous control experiments confirmed the specificity of these results. Attempts to produce specific staining within heart tissue were unsuccessful. Primary cultures of rat fetal hippocampal neurons permitted the study of CYP11B1 and CYP11B2 expression within a homogenous neuronal cell type. This work is described in chapter 6. CYP11B1 and CYP11B2 transcription and translation within these neuronal cells was demonstrated by the techniques used previously. In addition, the substrate DOC was incubated with the cells for 24-hour periods. Upon extraction and partial purification, the aldosterone and corticosterone content of the cell medium was measured by radioimmunoassay and shown to be significantly higher than that of control medium incubated in the absence of DOC. In summary, this thesis provides compelling evidence of the production of aldosterone and corticosterone within the rat central nervous system. It also includes detailed information concerning the distribution of the aldosterone synthase and 11 p- hydroxylase enzymes that produce these steroids. Finally, it demonstrates that 3 neuronal cells cultured from the fetal rat hippocampus are capable of converting DOC into their respective products. These findings could have profound implications for the diverse physiological processes that are regulated by corticosterone and aldosterone. 4 Declaration I declare that, unless specified otherwise in the text, the work presented in this thesis is my own. Scott M. MacKenzie 5 List of Contents Title Page 1 Abstract 2 Declaration 5 List of Contents 6 List of Figures 11 List of Tables 15 Dedication 16 Acknowledgements 16 Publications 17 Abbreviations 18 Corticosteroid Production In Adrenal And Extra-Adrenal Tissues: 21 A Review Introduction 21 Corticosteroid Biosynthesis 22 The corticosteroids 22 Cholesterol translocation 22 Cytochrome P450 enzymes 25 Biosynthetic pathways 26 The CYP1 IB Genes 32 The human CYP11B genes 32 The rat CYP1 IB genes 32 The CYP11B gene promoters and transcription factors 34 Regulation of Corticosteroid Secretion 39 Adrenocorticotrophic hormone (ACTH) 39 Angiotensin II (Angll) 44 Potassium 48 Neuroactive substances as agonists of adrenal function 48 Corticosteroid Action And Effects 51 Classical corticosteroid action 51 The mineralocorticoid and glucocorticoid receptors 52 Classical mineralocorticoid effects 55 Classical glucocorticoid effects 56 6 The 11 p-hydroxysteroid dehydrogenases 57 Nongenomic corticosteroid effects 59 Extra-Adrenal Corticosteroid Synthesis 61 Production of adrenal corticosteroids in the cardiovascular 61 system Corticosteroid Action In The Central Nervous System 65 Structure and general functions of the brain 65 Central mineralocorticoid and glucocorticoid receptors 67 11 P-Hydroxysteroid dehydrogenases in the brain 69 Corticosteroids and brain function 71 Central effects of corticosteroid deficiency and excess 81 Long-term potentiation and memory 84 Central corticosteroids and the hypothalamo-pituitary-adrenal 84 axis Stress, physiological disorders and ageing 86 Central effects of corticosteroids on blood pressure 89 Corticosteroid Production In The Central Nervous System 93 Materials And Methods 100 Reverse-Transcription Polymerase Chain Reaction (RT-PCR) And 100 Southern Blotting Of Steroidogenic Gene Transcripts RNA isolation 100 Analysis of isolated RNA 101 Reverse transcription 102 Oligonucleotide synthesis 103 PCR of first strand cDNA 103 Agarose gel preparation and electrophoresis 104 Southern blotting 105 Radioactive labelling of probes 106 Hybridisation and washes 106 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) And 107 Immunoblotting Antibody production 107 Tissue homogenisation 108 7 Determination of protein concentration 109 Polyacrylamide gel preparation 110 Precipitation of protein for electrophoresis 111 Protein transfer 112 Blocking and antibody incubation 112 Signal detection 113 Native PAGE and immunoblotting 114 Preparation And Immunostaining Of Cryosections 114 Preparation of cryosections 114 Immunostaining of cryosections (ABC protocol) 115 Preparation And Immunostaining Of Paraffin-Embedded Tissue 116 Sections Preparation of paraffin-embedded tissue sections 116 Deparaffinisation and rehydration of tissue sections 116 Antigen-retrieval pretreatments of paraffin-embedded tissue 117 sections Immunostaining of paraffin-embedded tissue sections (ABC 117 protocol) Immunostaining of paraffin-embedded tissue sections (CSA kit 118 protocol) Quenching of antibody binding by antigenic peptides 119 Preparation And Immunostaining Of Fetal Hippocampal Neurons 120 Preparation of fetal hippocampal neurons for immunostaining 120 Immunostaining of fetal hippocampal neurons 120 In Vitro Conversion Of 3H-DOC And DOC To Aldosterone And 121 Corticosterone By Fetal Hippocampal Neurons Preparation of fetal hippocampal neurons for steroid conversion 121 studies DNase treatment of RNA 121 Steroid conversion experiments 122 Measurement of tritiated steroid products 122 Measurement of nonradioactive steroid products 123 GCMS identification of aldosterone 123 8 Results: Reverse Transcription Polymerase Chain Reaction fRT- 125 PCR) And Southern Blotting Of Steroidogenic Gene Transcripts Introduction 125 Methods 126 Results 127 Adrenodoxin 127 CYP11A1 127 CYP11B1 128 CYP11B2 128 CYP11B3 128 Discussion 133 Results: SDS-Polvacrvlamide Gel Electrophoresis (SDS-PAGEI 139 And Immunoblotting Introduction 139 Methods 139 Results 140 Discussion 142 Results: Detection Of 11 P-Hvdroxvlase & Aldosterone Svnthase 148 In Adrenal And Extra-Adrenal Tissue By Immunostaining Introduction 148 Methods 148 Results 149 Discussion 151 Results: Corticosteroid Production Bv Primary Cultures Of Fetal 172 Rat Hippocampal Neurons Introduction 172 Methods 172 Results 173 RT-PCR 173 Immunostaining 173 Conversion of tritiated DOC to aldosterone and corticosterone 177 9 6.3.4 Conversion of unlabelled DOC to aldosterone and 177 corticosterone 6.3.5
Recommended publications
  • Compositions Comprising Drospirenone Molecularly
    (19) & (11) EP 1 748 756 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/107 (2006.01) 29.04.2009 Bulletin 2009/18 A61K 9/48 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) (2006.01) (2006.01) (21) Application number: 05708751.2 A61K 9/70 A61K 31/565 (22) Date of filing: 10.03.2005 (86) International application number: PCT/IB2005/000665 (87) International publication number: WO 2005/087194 (22.09.2005 Gazette 2005/38) (54) COMPOSITIONS COMPRISING DROSPIRENONE MOLECULARLY DISPERSED ZUSAMMENSETZUNGEN AUS DROSPIRENON IN MOLEKULARER DISPERSION DES COMPOSITIONS CONTENANT DROSPIRENONE A DISPERSION MOLECULAIRE (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • FUNKE, Adrian HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR D-14055 Berlin (DE) Designated Extension States: • WAGNER, Torsten AL BA HR MK YU 13127 Berlin (DE) (30) Priority: 10.03.2004 EP 04075713 (74) Representative: Wagner, Kim 10.03.2004 US 551355 P Plougmann & Vingtoft a/s Sundkrogsgade 9 (43) Date of publication of application: P.O. Box 831 07.02.2007 Bulletin 2007/06 2100 Copenhagen Ø (DK) (60) Divisional application: (56) References cited: 08011577.7 / 1 980 242 EP-A- 1 260 225 EP-A- 1 380 301 WO-A-01/52857 WO-A-20/04022065 (73) Proprietor: Bayer Schering Pharma WO-A-20/04041289 US-A- 5 569 652 Aktiengesellschaft US-A- 5 656 622 US-A- 5 789 442 13353 Berlin (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20120129819A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0129819 A1 Vancaillie et al. (43) Pub. Date: May 24, 2012 (54) GEL COMPOSITIONS FOR Publication Classi?cation ADMINISTRATION OF (51) Int Cl PHARMACEUTICALLY ACTIVE A 61K 31/565 (200601) COMPOUNDS A61P 31/00 (2006.01) A61P 29/00 2006.01 (75) Inventors: Thierry Vancaillie, Castlecrag A 611, 5/24 g2oo6~olg (AU), Alan Hewitt, Wrexham (GB) A611) 13/00 (200601) A61P 23/00 2006.01 (73) Assignee: Medortus (UK) Ltd, Wrexham A611; 25/04 E200601; (GB) A61P 1 7/00 (2006.01) A61P 15/00 (2006.01) (21) Appl' No" 13/264311 (52) us. Cl. ........................ .. 514/170; 514/182; 514/171 (22) PCT Filed: Apr. 14, 2010 (57) ABSTRACT (86) PCT No... PCT/AU10/00408 The P resent invention P rovides a P harmaceutical com P osition in the form of a Water-based gel comprising: at least one § 371 (6X1), pharmaceutically active compound; at least one gelling agent; (2)’ (4) Date; Feb 9, 2012 a solubilising agent; and Water, Wherein said composition is free or substantially free of unsubstituted monohydric alco (30) Foreign Application Priority Data hols having between 1 and 6 carbon atoms. The invention also relates to methods for preparing the compositions and uses Apr. 14, 2009 (AU) .............................. .. 2009901585 thereof. US 2012/0129819 A1 May 24, 2012 GEL COMPOSITIONS FOR ders (such as skin disorders), a compound useful in the con ADMINISTRATION OF trol of infection, a compound useful in the treatment of PHARMACEUTICALLY ACTIVE in?ammatory conditions, a compound useful in the treatment COMPOUNDS of sexual dysfunction, a compound useful in the treatment of urological disorders, a compound useful in anaesthesia, an TECHNICAL FIELD analgesic compound, a compound Which is an ot-adrenergic [0001] The present invention relates to Water-based gel receptor agonist, a hormone or a prohormone.
    [Show full text]
  • Drug Insight: Eplerenone, a Mineralocorticoid- Receptor Antagonist Frances Mcmanus, Gordon T Mcinnes and John MC Connell*
    REVIEW www.nature.com/clinicalpractice/endmet Drug Insight: eplerenone, a mineralocorticoid- receptor antagonist Frances McManus, Gordon T McInnes and John MC Connell* SUMMARY INTRODUCTION The traditional perception of aldosterone as a Increasing recognition of the role of aldosterone in cardiovascular disease hormone of the adrenal zona glomerulosa with has been supported by a significant body of evidence from animal models. actions limited to sodium and water homeostasis This evidence has been translated into clinical practice, and large-scale, is now recognized as incomplete. Nonclassical randomized, placebo-controlled trials have confirmed the beneficial effects of mineralocorticoid blockade in patients with heart failure. As a actions of aldosterone in a variety of nonepithelial target tissues have been demonstrated;1 rapid, consequence, there has been a resurgence in the use of mineralocorticoid- 2 receptor antagonists in clinical practice that has prompted the search nongenomic effects have been identified, and the possibility of local renin–angiotensin–aldosterone for a potent and specific antagonist without the sexual side effects of 3 spironolactone. Eplerenone, a mineralocorticoid-receptor antagonist systems (RAAS) has been suggested. Increasing with minimal binding to the progesterone and androgen receptors, is recognition of aldosterone as a key cardiovascular now licensed for treatment of heart failure in Europe and heart failure hormone has provoked interest in the therapeutic and hypertension in the US; it has also been proposed as a treatment for use of mineralocorticoid-receptor antagonism in a variety of cardiovascular conditions. This article reviews the current a variety of clinical presentations. The adverse- concepts of the actions of aldosterone at a cellular level.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]
  • Autacoids Introduction
    AUTACOIDS INTRODUCTION • AUTACOIDS auto=self akos=healing/remedy • Local Hormones CLASSIFICATION • Amine derived: Histamine (amino acid: Histidine), Serotonin (Tryptophan) • Peptide derived: Angiotensin, Bradykinin • Lipid derived: Prostaglandins, Leukotrienes, Interleukins, Platelet Activating Factor, etc. FUNCTIONS • Physiological • Pathophysiological (Reaction to injuries) • Transmission and Modulation AMINE AUTACOIDS • DERIVED FROM NATURAL AMINO ACIDS • HISTAMINE AND SEROTONIN are the major autacoids in this class HISTAMINE NH2 5 4 1 3 N N H 2 Histamine INTRODUCTION • Imidazole ethylamine • Formed from the amino acid Histidine • Important inflammatory mediator • Potent biogenic amine and plays an important role in inflammation, anaphylaxis, allergies, gastric acid secretion and drug reaction • As part of an immune response to foreign pathogens, its produced by Basophils and mast cells found in nearby connective tissues. SITES OF HISTAMINE RELEASE 1) Mast cell site: Pulmonary tissue (mucosa of bronchial tree) • Skin • GIT(intestinal mucosa) • Conc. Of histamine is particularly high in these tissues 2) Non-mast cell sites: • CNS (neurons) • Epidermis of skin. • GIT(gastric cells) • Cells in regenerating or rapidly growing tissues • Basophils (in the blood) MECHANISM OF RELEASE • Histamine held by an acidic protein and heparin within intracellular granules → Granules extrude by exocytosis → Na+ gets exchanged for histamine • Substances released during IgG or lgM immunoreactions release histamine from the mast cells & basophil. • Chemical
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al
    US 200400.58896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich et al. (43) Pub. Date: Mar. 25, 2004 (54) PHARMACEUTICAL PREPARATION (30) Foreign Application Priority Data COMPRISING AN ACTIVE DISPERSED ON A MATRIX Dec. 7, 2000 (EP)........................................ OO126847.3 (76) Inventors: Rango Dietrich, Konstanz (DE); Publication Classification Rudolf Linder, Kontanz (DE); Hartmut Ney, Konstanz (DE) (51) Int. Cl." ...................... A61K 31156; A61K 31/4439 (52) U.S. Cl. ........................... 514/171; 514/179; 514/338 Correspondence Address: (57) ABSTRACT NATH & ASSOCATES PLLC 1030 FIFTEENTH STREET, N.W. The present invention relates to the field of pharmaceutical SIXTH FLOOR technology and describes a novel advantageous preparation WASHINGTON, DC 20005 (US) for an active ingredient. The novel preparation is Suitable for 9 producing a large number of pharmaceutical dosage forms. (21) Appl. No.: 10/433,398 In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix com (22) PCT Filed: Dec. 6, 2001 posed of one or more excipients Selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid (86) PCT No.: PCT/EPO1/14307 eSter. US 2004/0058896 A1 Mar. 25, 2004 PHARMACEUTICAL PREPARATION 0008 Further subject matters are evident from the claims. COMPRISING AN ACTIVE DISPERSED ON A MATRIX 0009. The preparations for the purpose of the invention preferably comprise numerous individual units in which at least one active ingredient particle, preferably a large num TECHNICAL FIELD ber of active ingredient particles, is present in an excipient 0001. The present invention relates to the field of phar matrix composed of the excipients of the invention (also maceutical technology and describes a novel advantageous referred to as active ingredient units hereinafter).
    [Show full text]
  • A Computational Study of the Substrate Conversion and Selective Inhibition of Aldosterone Synthase
    A computational study of the substrate conversion and selective inhibition of aldosterone synthase Citation for published version (APA): Roumen, L. (2008). A computational study of the substrate conversion and selective inhibition of aldosterone synthase. Technische Universiteit Eindhoven. https://doi.org/10.6100/IR637195 DOI: 10.6100/IR637195 Document status and date: Published: 01/01/2008 Document Version: Publisher’s PDF, also known as Version of Record (includes final page, issue and volume numbers) Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.
    [Show full text]
  • European Patent Office of Opposition to That Patent, in Accordance with the Implementing Regulations
    (19) & (11) EP 1 748 756 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/107 (2006.01) 29.04.2009 Bulletin 2009/18 A61K 9/48 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) (2006.01) (2006.01) (21) Application number: 05708751.2 A61K 9/70 A61K 31/565 (22) Date of filing: 10.03.2005 (86) International application number: PCT/IB2005/000665 (87) International publication number: WO 2005/087194 (22.09.2005 Gazette 2005/38) (54) COMPOSITIONS COMPRISING DROSPIRENONE MOLECULARLY DISPERSED ZUSAMMENSETZUNGEN AUS DROSPIRENON IN MOLEKULARER DISPERSION DES COMPOSITIONS CONTENANT DROSPIRENONE A DISPERSION MOLECULAIRE (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • FUNKE, Adrian HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR D-14055 Berlin (DE) Designated Extension States: • WAGNER, Torsten AL BA HR MK YU 13127 Berlin (DE) (30) Priority: 10.03.2004 EP 04075713 (74) Representative: Wagner, Kim 10.03.2004 US 551355 P Plougmann & Vingtoft a/s Sundkrogsgade 9 (43) Date of publication of application: P.O. Box 831 07.02.2007 Bulletin 2007/06 2100 Copenhagen Ø (DK) (60) Divisional application: (56) References cited: 08011577.7 / 1 980 242 EP-A- 1 260 225 EP-A- 1 380 301 WO-A-01/52857 WO-A-20/04022065 (73) Proprietor: Bayer Schering Pharma WO-A-20/04041289 US-A- 5 569 652 Aktiengesellschaft US-A- 5 656 622 US-A- 5 789 442 13353 Berlin (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • STARLING REVIEW the New Biology of Aldosterone
    1 STARLING REVIEW The new biology of aldosterone .. John M C Connell and Eleanor Davies MRC Blood Pressure Group, Division of Cardiovascular and Medical Sciences, University of Glasgow, Gardiner Institute, Western Infirmary, Glasgow G11 6NT, UK (Requests for offprints should be addressed to J M C Connell; Email: [email protected]) Abstract Classically, aldosterone is synthesised in the adrenal zona principal source of circulating and locally available glomerulosa and binds to specific mineralocorticoid hormone. receptors located in the cytosol of target epithelial cells. Recent studies have shown major therapeutic benefits of Translocation of the resulting steroid receptor complex to mineralocorticoid receptor antagonism in cardiac failure, the cell nucleus modulates gene expression and translation which emphasise the importance of aldosterone in caus- of specific ‘aldosterone-induced’ proteins that regulate ing adverse cardiovascular pathophysiological effects. electrolyte and fluid balance. However, non-epithelial Additional evidence demonstrates that aldosterone levels and rapid non-genomic actions of aldosterone have also predict development of high blood pressure in normo- been described that account for a variety of actions of tensive subjects, while it is now clear that increased aldosterone that contribute to blood pressure homeostasis. aldosterone action contributes to hypertension and cardio- These include key actions on endothelial cells and on vascular damage in approximately 10% of patients with cardiac tissue. established hypertension. There is also evidence that aldosterone can be syn- These new findings highlight the role of aldosterone as thesised in other tissues; the most convincing evidence a key cardiovascular hormone and extend our understand- relates to the central nervous system.
    [Show full text]
  • Molecular Evolution of the Switch for Progesterone and Spironolactone from Mineralocorticoid Receptor Agonist to Antagonist
    Molecular evolution of the switch for progesterone and spironolactone from mineralocorticoid receptor agonist to antagonist Peter J. Fullera,b,1, Yi-Zhou Yaoa,b, Ruitao Jinc, Sitong Hec, Beatriz Martín-Fernándeza,b,2, Morag J. Younga,b, and Brian J. Smithc aCentre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia; bDepartment of Molecular Translational Science, Monash University, Clayton, VIC 3168, Australia; and cLa Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC 3086, Australia Edited by Huda Akil, University of Michigan, Ann Arbor, MI, and approved July 29, 2019 (received for review February 25, 2019) The mineralocorticoid receptor (MR) is highly conserved across In the present study, we demonstrate that a single residue change vertebrate evolution. In terrestrial vertebrates, the MR mediates is responsible for the switch from an agonist response to progesterone sodium homeostasis by aldosterone and also acts as a receptor for for zebrafish MR (zMR) to antagonist for human MR (hMR). This cortisol. Although the MR is present in fish, they lack aldosterone. change in the MR ligand-binding domain (LBD) is surprisingly dis- The MR binds progesterone and spironolactone as antagonists in tant from the ligand-binding site and has not previously been asso- human MR but as agonists in zebrafish MR. We have defined the ciated with agonist to antagonist switching in the MR. molecular basis of these divergent responses using MR chimeras between the zebrafish and human MR coupled with reciprocal Results site-directed mutagenesis and molecular dynamic (MD) simulation LBD Mediates the Agonist Response of the Zebrafish MR to based on the crystal structures of the MR ligand-binding domain.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,715,735 B2 Funke Et Al
    US008715735B2 (12) United States Patent (10) Patent No.: US 8,715,735 B2 Funke et al. (45) Date of Patent: May 6, 2014 (54) STABILISED SUPERSATURATED SOLIDS OF OTHER PUBLICATIONS LIPOPHILIC DRUGS V. Buehler, “Kollidon (R). Polyvinylpyrrollidone for the pharmaceu (75) Inventors: Adrian Funke, Berlin (DE); Torsten tical industry.” Mar. 1998, BASF AG Fine Chemicals, Ludwigshafen, Wagner, Berlin (DE); Ralph Lipp, Germany, pp. 88-116, XP002297940. Zionsville, IN (US) K. Khougaz et al., “Crystallization inhibition in solid dispersions of (73) Assignee: Bayer Intellectual Property GmbH, MK-0591 and poly(vinylpyrrollidone)polymers,” Journal of Pharma Monehim (DE) ceutical Sciences, Oct. 2000, vol. 89, No. 10, pp. 1325-1334. XP002297939, the whole document. (*) Notice: Subject to any disclaimer, the term of this T. Watanabe et al., "Stability of amorphous indomethacin com patent is extended or adjusted under 35 pounded with silica.” International Journal of Pharmaceutics, U.S.C. 154(b) by 759 days. 2001, vol. 226, pp. 81-91, XP002310637. (21) Appl. No.: 11/076,022 T. Watanabe et al., “Prediction of apparent equilibrium solubility of indomethacin compounded with silica by 13C solid state NMR.” Int. (22) Filed: Mar 10, 2005 J. Pharmaceutics, 2002, vol. 248, pp. 123-129, XP002310638. (65) Prior Publication Data T. Watanabe et al., “Comparison between polyvinylpyrrollidone and silica nanoparticles as carriers for indomethacin in a solid state dis US 2005/02O7990 A1 Sep. 22, 2005 persion.” Int. J. Pharmaceutics, 2003, vol. 250, pp. 283-286, XPOO23 10639. Related U.S. Application Data H. Takeuchi et al., “Spherical Solid dispersion containing amorphous tolbutamide embedded in enteric coating polymers or colloidal silica (60) Provisional application No.
    [Show full text]